Page 55 - InsideOut Magazine

ClinicalTrials
The latest research making therapies available to patients.
Novartis Pharmaceuticals and the University of Pennsylvania are sponsoring a multi-center, Phase II study to determine the efficacy and safety of an experimental therapy called CTL019 T-cells in pediatric patients with B-cell acute lymphoblastic leukemia, who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic stem cell transplant. The study includes both relapsed and refractory B-cell acute lymphoblastic leukemia. Eligibility requirements include, but are not limited to, cancer patients between the ages of two and 21. Estimated study completion is August 2017. NCT02228096.
Pfizer is sponsoring and recruiting participants for a Phase I study evaluat- ing PF-05212384 (PI3K/mTOR inhibitor) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors. The study will assess the safety, pharmacokinetics and pharmacodynamics of these combina- tions in patients with advanced cancer
in order to determine the maximum tolerated dose in each combination. Eligibility requirements include, but are not limited to, both genders 18 years and older. Estimated study completion date is January 2016. NCT01920061.
The Medicines Company is sponsor- ing a Phase I trial to evaluate the pharmacokinetics, safety and tolerability of oritavancin in patients under the age of 18 with a confirmed or suspected bacte- rial infection. Eligibility requirements include, but are not limited to, patients under the age of 18 with a suspected
or confirmed Gram positive bacterial infection who are receiving antibiotic therapy. Estimated study completion is December 2016. NCT02134301.
Ariad Pharmaceuticals is sponsor- ing a Phase II study to evaluate the efficacy and safety of two different dosing regimens of AP26113 in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on therapy with crizotinib. Eligibility requirements include, but are not limited to, both genders 18 years and older. Estimated study completion is November 2017. NCT02094573.
Now recruiting participants throughout the U.S., Octapharma is sponsoring a two arm non-interventional trial that will compare the occurrence of adverse drug reactions between Octagam 5% and other marketed IVIG infusion treatments.
Eligibility requirements include, but are not limited to, patients over 18 years with primary immune deficiency syndrome receiving marketed IVIG as treatment. Estimated study completion is August 2016. NCT01859754.
Baxter Healthcare Corporation
is sponsoring a Phase IV study to compare the hemostatic efficacy and safety of continuous infusion versus intermittent bolus infusion in the peri- and post-operative setting. Study will employ a recombinant antihemophilic factor manufactured without added human or animal proteins, in previously treated patients with severe or moder- ately severe hemophilia A, and who are undergoing unilateral major orthopedic surgery that requires drain replacement. Eligibility requirements include, but are not limited to, patients between 18 and 70 years of age. Estimated study comple- tion is August 2017. NCT00357656.
Source: ClinicalTrials.gov, November 2014
To get information quickly
on the studies, access
Tip! ClinicalTrials.gov and type in the identifier
number.
i.e., NCT01850004
ASD Healthcare | 53